EMERYVILLE, Calif., January 22, 2018 — Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing
EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on improving the safety profile of T cell therapies and developing novel T
September 13, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif.–(BUSINESS WIRE)– Eureka Therapeutics, Inc., a clinical stage biotechnology company focused on developing novel T-cell immunotherapies for
POTENTIAL TO ACCELERATE APPLICATION OF CAR-T THERAPY TO OTHER SOLID TUMORS June 07, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. & DUARTE, Calif. -Eureka
April 20, 2017 08:00 AM Eastern Daylight Time EMERYVILLE, Calif. -Eureka Therapeutics, Inc., a biotechnology company focused on developing novel T-cell immunotherapies for the treatment
Eureka’s manuscript on targeting alpha-fetoprotein (AFP) with a CAR T cell therapy for the treatment of liver cancer is published in Clinical Cancer Research on August
EMERYVILLE, Calif. & NEW YORK & SEATTLE, Aug 4th, 2016 – Eureka Therapeutics, Inc. and Memorial Sloan Kettering Cancer Center(MSK) announced today an exclusive license agreement
EMERYVILLE, CA, Jan. 7th, 2016 – Eureka Therapeutics, Inc. announced today that Memorial Sloan Kettering Cancer Center and Juno Therapeutics, Inc. (Nasdaq: JUNO) have entered into
Eureka’s co-authored paper “Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1,” was published on Monday in Nature Biotechnology. The paper describes a bispecific antibody against intracellular antigen
Emeryville, CA – May 21, 2015 – Eureka Therapeutics Inc. and Boehringer Ingelheim announced today that they have entered into a research agreement for the